                         SEQUENCE LISTING

<110>  Du-Shieng CHIEN
 
<120>  NODAL REGULATION OF CANCER DRUG RESISTANCE GENE

<130>  10030-008US

<150>  62797270
<151>  2019-01-26

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-Nodal antibody light chain

<400>  1

Asp Ile Lys Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile His Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro His 
                85                  90                  95      


Val Arg Cys Trp Asp Gln Ala Gly Thr Glu Thr Glu Ala Trp 
            100                 105                 110 


<210>  2
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-Nodal antibody heavy chain


<220>
<221>  misc_feature
<222>  (120)..(120)
<223>  Xaa can be any naturally occurring amino acid

<400>  2

Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser 
1               5                   10                  15      


Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala 
            20                  25                  30          


Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala 
        35                  40                  45              


Ser Ile Ser Ser Gly Gly Cys Thr Tyr Tyr Pro Asp Ser Val Lys Gly 
    50                  55                  60                  


Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Ile Leu Tyr Leu Gln 
65                  70                  75                  80  


Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
                85                  90                  95      


Gly Ser Met Ile Thr Ala Asp Gly Asn Ser Leu Leu Leu Cys Tyr Gly 
            100                 105                 110         


Leu Leu Gly Ser Arg Asn Leu Xaa His Arg 
        115                 120         


<210>  3
<211>  110
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-Nodal antibody heavy chain C

<400>  3

Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met 
1               5                   10                  15      


Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Arg Asn Tyr Trp Met 
            20                  25                  30          


Ser Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu 
        35                  40                  45              


Ile Arg Leu Lys Ser Asp Asn Tyr Ala Ala Arg Tyr Ala Glu Ser Val 
    50                  55                  60                  


Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys 
                85                  90                  95      


Thr Gly Ile Arg Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu 
            100                 105                 110 


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL1

<400>  4

Gly Asn Ile His Asn Tyr Leu Ala 
1               5               


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL2

<400>  5

Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp 
1               5                   10      


<210>  6
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRL3

<400>  6

Gln His Phe Trp Ser Thr Pro His Val Arg Cys Trp Asp Gln Ala 
1               5                   10                  15  


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH1

<400>  7

Phe Thr Phe Ser Ser Tyr Ala Met Ser 
1               5                   


<210>  8
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH2

<400>  8

Trp Val Ala Ser Ile Ser Ser Gly Gly Cys Thr Tyr Tyr 
1               5                   10              


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CDRH3

<400>  9

Ala Arg Gly Ser Met Ile Thr Ala Asp Gly Asn 
1               5                   10      


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain C CDRH1 sequence

<400>  10

Phe Thr Phe Arg Asn Tyr Trp Met Ser 
1               5                   


<210>  11
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain C CDRH2 sequence

<400>  11

Trp Val Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Ala Arg Tyr 
1               5                   10                  15      


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  heavy chain C CDRH3 sequence

<400>  12

Gly Ile Arg Arg Phe Ala Tyr 
1               5           


